In the prognostic model, stanniocalcin 2 (STC2), as a potential biomarker expressed highly in hepatocellular carcinoma tissues with a reduction in the overall survival ratio of those patients, was significantly upregulated in Nrf1α-deficient cells, but strikingly downregulated in Nrf2-deficient cells 414. The gene discussed is NFE2L2; the disease is hepatocellular carcinoma.